Sputnik V: Russia-India new agreement on production of 200 million doses

The Russian Direct Investment Fund (RDIF) has reached an agreement with the Indian pharmaceutical company Virchow Biotech to produce 200 million doses of the vaccine in India. Sputnik V against covid-19.

“The technology transfer is expected to be completed in the second quarter of 2021 and will be followed by large-scale commercial production,” said RDIF, which partially funds the development of the Russian vaccine and is negotiating agreements to produce it outside. Russia, as explained by AMPE.

The deal follows another one announced last week with Indian pharmaceutical company Stelis, which is to produce 200 million doses.

RDIF agreed in November with Indian company Hetero to produce more than 100 million doses of the vaccine annually.

“Vaccine partnerships are the only way to overcome the pandemic. “People are still fighting the coronavirus and we are seeing a growing interest in Sputnik V,” said Kirill Dmitriev, head of RDIF.

The Russian vaccine against her covid-19, which has been licensed in about 50 countries, has not been approved in India, where clinical trials are ongoing. But Moscow is trying to diversify its vaccine production sources, as its own capabilities are limited and global demand is high.

You may also like